ARTICLE | Management Tracks
Plus: Phillip Dennis joins I-Mab as CMO, and an update from Exscientia
By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst
June 7, 2024 12:51 AM UTC
Boston Pharmaceuticals Inc. hired Margaret Koziel as CMO, succeeding acting CMO Juan Carlos Lopez-Talavera, who will become an adviser. Koziel was CMO at Innoviva Inc. (NASDAQ:INVA) and Axcella Health Inc. (NASDAQ:AXLA). Boston’s most advanced program is BOS-580, a FGF21 analogue, for metabolic dysfunction-associated steatohepatitis (MASH).
Cancer play I-Mab (NASDAQ:IMAB) hired Phillip Dennis as CMO, effective June 17. Dennis was VP of lung cancer strategy and global project head for an antibody-drug conjugate at Sanofi (Euronext:SAN; NASDAQ:SNY)…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652634/boston-pharma-names-margaret-koziel-cmo